| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| 144 | Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing |
Other
|
||
| SC 13G/A | An amendment to the SC 13G filing |
Other
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| SC 13D/A | An amendment to a SC 13D filing |
Other
|
||
| 8-K/A | Amendment to a previously filed 8-K |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| 8-K/A | Amendment to a previously filed 8-K |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| RW | Withdrawal of registration statement filed under the Securities Act |
Other
|
||
| SC 13D/A | An amendment to a SC 13D filing |
Other
|
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
